1370. Cefepime/VNRX-5133 Broad-Spectrum Activity Is Maintained Against Emerging KPC- and PDC-Variants in Multidrug-Resistant K. pneumoniae and P. aeruginosa

BACKGROUND: VNRX-5133 is a cyclic boronate β-lactamase inhibitor (BLI) currently in clinical development with cefepime to treat multidrug-resistant (MDR) infections caused by ESBL- and carbapenemase-producing Enterobacteriaceae (ENT) and P. aeruginosa (PSA). VNRX-5133 has direct inhibitory activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Daigle, Denis, Hamrick, Jodie, Chatwin, Cassandra, Kurepina, Natalia, Kreiswirth, Barry N, Shields, Ryan K, Oliver, Antonio, Clancy, Cornelius J, Nguyen, Minh-Hong, Pevear, Daniel, Xerri, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252657/
http://dx.doi.org/10.1093/ofid/ofy210.1201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252657/
http://dx.doi.org/10.1093/ofid/ofy210.1201

Ejemplares similares